Shopping Cart
Remove All
Your shopping cart is currently empty
(-)-p-Bromotetramisole Oxalate (6-Bromolevamisole oxalate) is a potent and non-specific inhibitor of alkaline phosphatase.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $43 | In Stock | In Stock | |
| 50 mg | $57 | In Stock | In Stock | |
| 100 mg | $102 | In Stock | In Stock | |
| 500 mg | $248 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
| Description | (-)-p-Bromotetramisole Oxalate (6-Bromolevamisole oxalate) is a potent and non-specific inhibitor of alkaline phosphatase. |
| In vitro | Aurora A Inhibitor I is a 2,4-dianilinopyrimidine that selectively and potently inhibits Aurora A. Aurora A Inhibitor I effectively inhibits the proliferation of HCT116 and HT29 cells, with IC50 of 190 nM and 2.9 μM, respectively. The Aurora A selectivity of Aurora A Inhibitor I against Aurora B depends on a single amino acid (Thr217) of Aurora A. [1] In KCL-22 cells, Aurora A Inhibitor I (1-5 μM) increases G2/M cell fraction, induces histone H3 serine 10 phosphorylation, and suppresses mitotic Aurora A autophosphorylation on Thr288. Aurora A Inhibitor I (0.5-5 μM) also suppresses cell proliferation in KCL-22 cells, as well as BCR-ABL-negative leukemia cell lines KG-1 and HL-60. Aurora A Inhibitor I effectively induces apoptosis in KCL-22 cells at 5 μM. [2] In a recent study, Aurora A Inhibitor I is also found to inhibit cell growth of HCT116, HT29, and HeLa cells, with IC50 of 377.6 nM, 5.6 μM, and 416 nM. [3] |
| Synonyms | L-p-Bromotetramisole oxalate, 6-Bromolevamisole oxalate, (-)-p-Bromolevamisole oxalate |
| Molecular Weight | 373.22 |
| Formula | C13H13BrN2O4S |
| Cas No. | 62284-79-1 |
| Smiles | OC(=O)C(O)=O.Brc1ccc(cc1)[C@H]1CN2CCSC2=N1 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 28 mg/mL (75.02 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 60 mg/mL (160.76 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.36 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.